Insider Selling: Allogene Therapeutics Inc (NASDAQ:ALLO) Major Shareholder Sells $2,008,124.68 in Stock

Allogene Therapeutics Inc (NASDAQ:ALLO) major shareholder Group Holdings (Sbs) Advis Tpg sold 47,767 shares of the firm’s stock in a transaction on Friday, June 19th. The stock was sold at an average price of $42.04, for a total value of $2,008,124.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Holdings (Sbs) Advis Tpg also recently made the following trade(s):

  • On Monday, June 22nd, Group Holdings (Sbs) Advis Tpg sold 172,425 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.83, for a total value of $7,384,962.75.
  • On Wednesday, June 17th, Group Holdings (Sbs) Advis Tpg sold 87,319 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.18, for a total value of $3,683,115.42.
  • On Monday, June 15th, Group Holdings (Sbs) Advis Tpg sold 129,154 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.14, for a total value of $5,442,549.56.
  • On Wednesday, June 3rd, Group Holdings (Sbs) Advis Tpg sold 487,402 shares of Allogene Therapeutics stock. The stock was sold at an average price of $47.40, for a total value of $23,102,854.80.

Shares of NASDAQ:ALLO opened at $43.60 on Thursday. The company has a current ratio of 18.81, a quick ratio of 18.81 and a debt-to-equity ratio of 0.08. Allogene Therapeutics Inc has a 12 month low of $17.43 and a 12 month high of $55.00. The company has a 50-day moving average price of $42.86 and a 200 day moving average price of $29.35. The company has a market cap of $5.37 billion, a price-to-earnings ratio of -21.91 and a beta of 2.01.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.58) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.58). As a group, equities analysts forecast that Allogene Therapeutics Inc will post -2.27 EPS for the current year.

ALLO has been the subject of a number of analyst reports. Roth Capital upgraded Allogene Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $26.00 to $60.00 in a research note on Tuesday, May 19th. HC Wainwright cut their price target on Allogene Therapeutics from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Guggenheim upgraded Allogene Therapeutics from a “neutral” rating to a “buy” rating in a research note on Friday, May 15th. Zacks Investment Research upgraded Allogene Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Thursday, April 2nd. Finally, Canaccord Genuity increased their price target on Allogene Therapeutics from $36.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $45.21.

Several large investors have recently made changes to their positions in the stock. Capital Research Global Investors lifted its holdings in shares of Allogene Therapeutics by 37.1% in the 1st quarter. Capital Research Global Investors now owns 8,972,571 shares of the company’s stock valued at $174,427,000 after acquiring an additional 2,429,893 shares during the last quarter. Capital International Investors lifted its stake in Allogene Therapeutics by 17.8% in the first quarter. Capital International Investors now owns 4,578,800 shares of the company’s stock worth $89,012,000 after purchasing an additional 690,779 shares during the last quarter. Regents of The University of California bought a new stake in Allogene Therapeutics in the fourth quarter worth about $61,077,000. Alliancebernstein L.P. lifted its stake in Allogene Therapeutics by 11.3% in the first quarter. Alliancebernstein L.P. now owns 1,976,724 shares of the company’s stock worth $38,428,000 after purchasing an additional 200,421 shares during the last quarter. Finally, State Street Corp lifted its stake in Allogene Therapeutics by 0.9% in the first quarter. State Street Corp now owns 1,694,216 shares of the company’s stock worth $32,936,000 after purchasing an additional 14,766 shares during the last quarter. 57.97% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Read More: What is the Rule of 72?

Insider Buying and Selling by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.